Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
33results about How to "Stable salt" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Indanyloxydihydrobenzofuranylacetic acids
InactiveUS20140163025A1Improve effectivenessImprove stabilityBiocideOrganic chemistryDiabetes mellitusDisease
The present invention relates to compounds of general formula I,wherein the groups (Het)Ar and R1 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
Owner:BOEHRINGER INGELHEIM INT GMBH
Indanyloxydihydrobenzofuranylacetic acids
The present invention relates to compounds of general formula I,wherein the group (Het)Ar is defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
Owner:BOEHRINGER INGELHEIM INT GMBH
New indanyloxydihydrobenzofuranylacetic acids
ActiveUS20130252937A1Improve effectivenessImprove stabilityBiocideOrganic chemistryDiseaseDiabetes mellitus
The present invention relates to compounds of general formula I,wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
Owner:BOEHRINGER INGELHEIM INT GMBH
Indanyloxyphenylcyclopropanecarboxylic acids
ActiveUS20130324514A1Improve effectivenessImprove stabilityBiocideMetabolism disorderDiseaseCarboxylic acid
The present invention relates to compounds of general formula I,wherein the groups R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
Owner:BOEHRINGER INGELHEIM INT GMBH
Indanyloxyphenylcyclopropanecarboxylic acids
ActiveUS8633182B2Improve effectivenessImprove stabilityBiocideOrganic compound preparationDiseaseCarboxylic acid
The present invention relates to compounds of general formula I,wherein the groups R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
Owner:BOEHRINGER INGELHEIM INT GMBH
Indanyloxydihydrobenzofuranylacetic acids
ActiveUS8642585B2Improve effectivenessImprove stabilityBiocideOrganic chemistryDiseaseDiabetes mellitus
Owner:BOEHRINGER INGELHEIM INT GMBH
Indanyloxydihydrobenzofuranylacetic acids
InactiveUS20120302566A1Improve effectivenessGood chemical stabilityBiocideOrganic chemistryDiseaseAcetic acid
The present invention relates to compounds defined by formula (I)wherein the variables R1, R2, R3, m, and n are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are activators of the receptor GPR40 and thus are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
Owner:BOEHRINGER INGELHEIM INT GMBH
Indanyloxydihydrobenzofuranylacetic acids
ActiveUS20140221349A1Improve effectivenessImprove stabilityBiocideOrganic chemistryDiabetes mellitusAcetic acid
Compounds of general formula Iwherein the group R1 is defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
Owner:BOEHRINGER INGELHEIM INT GMBH
Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
ActiveUS20190389815A1Improve effectivenessImprove stabilityOrganic active ingredientsOrganic chemistryDiseaseDiabetes types
The present invention relates to compounds of general formula I,wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
Owner:BOEHRINGER INGELHEIM INT GMBH
Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
ActiveUS10538490B2Improve effectivenessImprove stabilityOrganic chemistryMetabolism disorderDiseaseDiabetes mellitus
Owner:BOEHRINGER INGELHEIM INT GMBH
Indanyloxydihydrobenzofuranylacetic acids
ActiveUS20160235706A1Improve effectivenessImprove stabilityOrganic chemistryMetabolism disorderDiabetes mellitusDisease
Owner:BOEHRINGER INGELHEIM INT GMBH
Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
ActiveUS10603317B2Improve effectivenessImprove stabilityOrganic active ingredientsOrganic chemistryDiseaseDiabetes mellitus
Owner:BOEHRINGER INGELHEIM INT GMBH
New indanyloxydihydrobenzofuranylacetic acids
ActiveUS20130289074A1Improve effectivenessImprove stabilityBiocideOrganic chemistryDiseaseStereochemistry
The present invention relates to compounds of general formula I,wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
Owner:BOEHRINGER INGELHEIM INT GMBH
Indanyloxyphenylcyclopropanecarboxylic acids
ActiveUS20150148347A1Improve effectivenessImprove stabilityBiocideOrganic chemistryDiseaseCarboxylic acid
A compound of formula I,wherein the groups R1, R2, R3, X, m, and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
Owner:BOEHRINGER INGELHEIM INT GMBH
Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
ActiveUS20170037040A1Improve effectivenessImprove stabilityOrganic active ingredientsOrganic chemistryDiseaseCarboxylic acid
The present invention relates to compounds of general formula I,wherein the groups R, R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
Owner:BOEHRINGER INGELHEIM INT GMBH
Indanyloxyphenylcyclopropanecarboxylic acids
ActiveUS9308194B2Improve effectivenessImprove stabilityOrganic chemistryPeptide/protein ingredientsDiseaseCarboxylic acid
Owner:BOEHRINGER INGELHEIM INT GMBH
Indanyloxydihydrobenzofuranylacetic acids
Owner:BOEHRINGER INGELHEIM INT GMBH
Indanyloxydihydrobenzofuranylacetic acids
Owner:BOEHRINGER INGELHEIM INT GMBH
Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
ActiveUS9617251B2Improve effectivenessImprove stabilityOrganic active ingredientsOrganic chemistryDiseaseCarboxylic acid
Owner:BOEHRINGER INGELHEIM INT GMBH
Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
ActiveUS20180208560A1Improve effectivenessImprove stabilityOrganic active ingredientsOrganic chemistryDiseaseDiabetes mellitus
The present invention relates to compounds of formula I,wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
Owner:BOEHRINGER INGELHEIM INT GMBH
Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
ActiveUS20190352266A1Improve effectivenessImprove stabilityOrganic chemistryMetabolism disorderDiseaseMedicine
The present invention relates to compounds of general formula I,wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
Owner:BOEHRINGER INGELHEIM INT GMBH
Indanyloxydihydrobenzofuranylacetic acids
Compounds of general formula Iwherein the group R1 is defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
Owner:BOEHRINGER INGELHEIM INT GMBH
Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
ActiveUS10793530B2Improve effectivenessImprove stabilityOrganic active ingredientsOrganic chemistryDiseaseReceptor
Owner:BOEHRINGER INGELHEIM INT GMBH
Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
ActiveUS20190381037A1Improve effectivenessImprove stabilityOrganic active ingredientsOrganic chemistryDiseaseReceptor for activated C kinase 1
The present invention relates to compounds of general formula I,wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
Owner:BOEHRINGER INGELHEIM INT GMBH
Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
ActiveUS10253004B2Improve effectivenessImprove stabilityOrganic active ingredientsOrganic chemistryDiseaseDiabetes mellitus
The present invention relates to compounds of formula I,wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
Owner:BOEHRINGER INGELHEIM INT GMBH
Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
ActiveUS10550127B1Improve effectivenessImprove stabilityMetabolism disorderOrganic chemistry methodsDiseaseDiabetes mellitus
Owner:BOEHRINGER INGELHEIM INT GMBH
Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
ActiveUS20190241521A1Improve effectivenessImprove stabilityOrganic chemistryMetabolism disorderDisease causeStereochemistry
The present invention relates to compounds of general formula I,wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, including binding to the GPR40 receptor and modulating its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
Owner:BOEHRINGER INGELHEIM INT GMBH
Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
ActiveUS20180148411A1Improve effectivenessImprove stabilityOrganic active ingredientsOrganic chemistryDiseaseCarboxylic acid
The present invention relates to compounds of general formula I,wherein the groups R, R1, R2, R3, m and n are as defined herein, which compounds have valuable pharmacological properties, in particular their ability to bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular type 2 diabetes. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
Owner:BOEHRINGER INGELHEIM INT GMBH
Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
ActiveUS10913720B2Improve effectivenessImprove stabilityOrganic chemistryMetabolism disorderDiseaseDiabetes mellitus
The present invention relates to compounds of general formula I,wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
Owner:BOEHRINGER INGELHEIM INT GMBH
Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
ActiveUS20190375712A1Improve effectivenessImprove stabilityOrganic chemistryMetabolism disorderDiabetes mellitusMedicine
The present invention relates to compounds of general formula I,wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
Owner:BOEHRINGER INGELHEIM INT GMBH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com